Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in infants: randomized, observer-masked, single-center clinical study

Shilei Wang†, Jinrong Dong†, Wenqing Chai1, Fangjun Li2, Shuqiao Wang1, Bing Sun3 and Ze Chen1*

Abstract
The aim of this study is to further investigate the immune response of the inactivated split-virion vaccine for infants. We tested the immunogenicity and safety of the inactivated split-virion vaccine in infants, aged 6–35 months, for a randomized, observer-masked, age-stratified clinical study. We randomly divided subjects into three groups: 7.5 μg, 15 μg of hemagglutinin antigen dosage groups and seasonal influenza vaccine for children dosage group in a 2 dose regimen. A serologic analysis was performed at baseline and on day 21 and 42. 312 infants received a single dose injection of vaccine and 265 (84.94%) infants received two doses injection of vaccine. Adverse reactions were mostly mild or moderate. Among the subjects who received 7.5 μg and 15 μg of vaccine for a single dose injection, the rate of hemagglutinin inhibition titer of 1:40 or greater were 52.48% (95% confidence interval (CI) 42.83 ~ 61.95) and 61.11% (95% CI 50.78 ~ 70.53), respectively. Among the subjects receiving 7.5 μg and 15 μg of vaccine for two doses injection, the rate of hemagglutinin inhibition (HI) titer of 1:40 or greater were 90.10% (95% CI 82.73 ~ 94.53) and 94.44% (95% CI 87.64 ~ 97.60), respectively. These data suggests that 15 μg or 7.5 μg dose of hemagglutinin antigen of the inactivated split-virion vaccine was safe and two doses of injection could induce a sufficient protective immune response in infants.

Trial registration: Clinical trials registration: NCT01494740.

Keywords: Infant; Influenza; Vaccine; Immunogenicity

Introduction
In April, 2009, a previously undescribed influenza A (H1N1) virus was isolated from people in Mexico and the United States, and then spreaded rapidly to many countries around the world. On June 11, 2009, a new influenza pandemic was officially declared by World Health Organization (WHO) (Dawood et al. 2009; World Health Organization 2009a). As of 18 July 2010, more than 214 countries around the world and overseas territories or communities have reported laboratory confirmed cases of pandemic influenza H1N1 2009, including over 18366 deaths (World Health Organization 2010a). Across the reports of the 2009 influenza A (H1N1) virus infection cases, about 60% were young people less than 18 years of age, and the susceptibility of young children, which was further evidenced by the high hospitalization rates of those younger than 4 years (Centers for Disease Control and Prevention (CDC) 2009; Dawood et al. 2009).

The effectiveness of influenza vaccination in children to reduce the virus infection in the pandemic has been well demonstrated (Neuzil KM et al. 2001; Ruben 2004). Many countries and vaccine manufacturers have started to develop influenza vaccines against the 2009 influenza A (H1N1) virus, and evaluated the effect of vaccines in clinical trials. In Australia, the clinical trials have proved that one dose of the monovalent, split-virion vaccine without adjuvant was safe for people aged 18–64 years, and the seroconversion rates were 74.20% with 15 μg of

* Correspondence: chenze2005@hotmail.com
†Equal contributors
1Shanghai Institute of Biological Products, Shanghai 200052, China
2Full list of author information is available at the end of the article

© 2014 Wang et al; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
hemagglutinin antigen dosage (Greenberg et al. 2009). In determining the 2009 influenza A (H1N1) vaccine was safe and could induce strong immune responses in healthy adults, the immune effect of vaccine in people of a small age group was studied further. In China, clinical trials have evaluated the safety and immunogenicity of the 2009 influenza A (H1N1) vaccine in people aged 3–60 years and our results have been published on the WHO website (Liang XF et al. 2010; Ze & Yang 2010). In addition, we also reported the long-term immunogenicity of the 2009 influenza A (H1N1) vaccine in the people aged 18–60 years (Yang et al. 2012). Subsequently, some papers reported the immune response in people under the age of 3 with 15 μg and 30 μg of hemagglutinin antigen dosage, which proved that the 2009 influenza A (H1N1) vaccine was safe and could induce enough immune response.

Our main purpose is to assess the safety and immunogenicity of the monovalent, unadjuvanted, split-virion 2009 influenza A (H1N1) vaccine in infants. In our study, infants under the age of 3 were divided into three age groups: 6–12 months, 13–24 months and 25–35 months in order to study the immune effects of the vaccine in infants. We described the immune responses of infants aged 6–35 months after being given 2 doses of injection with 7.5 μg and 15 μg of hemagglutinin antigen.

**Methods**

**Study design**

From December 2009 to January 2010, we carried out the double-blind, single-center clinical trial in Luxi County, Xiangxi Autonomous Prefecture, Hunan Province (China). The purpose of this study was to evaluate the safety and immunogenicity of the split-virion 2009 influenza A (H1N1) vaccine in healthy infants aged 6–35 months and these infants were divided into three groups: aged 6–12 months, 13–24 months and 25–35 months. All subjects received two doses of 7.5 μg, 15 μg hemagglutinin antigen or seasonal influenza vaccine with intervals three weeks apart. All of the pilot programs, clinical manuals and other materials used in this study were consistent with the Declaration of Helsinki and the quality control requirements for clinical trials, and were approved by the Ethics Committee of Hunan Province.

**Vaccines**

The monovalent, inactivated, split-virion 2009 influenza A (H1N1) vaccine was developed by the Shanghai Institute of Biological Products, and the seed virus was prepared from the reassortant vaccine virus A/California/7/2009 NYMC X-179A, as recommended by the WHO (World Health Organization 2009b; World Health Organization 2010b). The vaccine was prepared in embryonated chicken eggs according to the standard techniques used in the production of seasonal influenza vaccine. In brief, the virus was amplified in chicken embryos, then harvested and inactivated with formaldehyde. The viral cultures were then concentrated and purified for use as the final vaccine. The experimental vaccines were split-virus products containing 7.5 μg of hemagglutinin antigen per dose (0.25 ml) and 15 μg of hemagglutinin antigen per dose (0.5 ml). The virus strains of the seasonal vaccine for children (SI) (A/Brisbane/59/2007 H1N1-like; A/Brisbane/10/2007 H3N2-like; and B/Brisbane/60/2008-like strains) were chosen according to the WHO recommendations for use in the 2009–10 influenza season (northern hemisphere winter). Vaccines contained 7.5 μg of hemagglutinin per strain per dose.

The vaccine was approved for clinical use by the Chinese National Institute for the Control of Pharmaceutical and Biological Products (China) and in full compliance with the Pharmacopoeia standards.

**Participants**

All subjects must be strictly in line with the standard of ages 6–35 months. Infants with confirmed or suspected 2009 influenza A (H1N1) infection or those who had received other influenza products within 6 months were excluded from the study and the eligible infants did not have history of allergy or contraindications to the vaccine. All the infants were full-term babies and weighed more than 2500 grams. All subjects participated voluntarily in the clinical trials and their written informed consent was obtained from the parent or guardian of the infants. The blind testing was designed by a third party at Central South University, who was not involved in other elements of the clinical trials.

Eligible infants were stratified in three groups by age: aged 6–12 months with 52 subjects, 13–24 months with 130 subjects and 25–35 months with 130 subjects. After stratification, infants were randomized to receive the 7.5 μg, 15 μg of hemagglutinin antigen or seasonal influenza vaccine.

Injections were given intramuscularly in the deltoid muscle and 21 days after vaccination, the subjects were inoculated with the same dose of vaccine. Because the injection volume differed in the study doses, we have taken measures to avoid affecting the results of clinical trial. Serum samples were collected before or on days 21, 42 after vaccination.

**Safety**

Induced local and systemic adverse events were recorded by the infant’s parent or guardian using a 7-day diary card, and other adverse events were recorded using a 21-day diary card. All local adverse events were considered related to the H1N1 vaccine. The systemic adverse events include: fever, allergic reactions, headache, fatigue, vomiting, diarrhea, coughing, crying, breastfeeding or eating disorders. The local adverse events include: (injection point) pain,
swelling, redness, ecchymosis, induration, itching. All adverse events tests and decisions were referred to the standards of the Division of Microbiology and Infectious Diseases, US National Institutes of Health (NIAID Division of Microbiology and Infectious Diseases 2007a; NIAID Division of Microbiology and Infectious Diseases 2007b).

**Immunogenicity**

The antibody titers against the vaccine strain were determined by HI assays of the anti-homologous strain of X-179A, performed in accordance with established measures using turkey erythrocytes. In brief, sera were firstly treated with receptor destroy enzyme at 36°C for 16 hours. The titers of HI antibody that were below the detection limit (i.e., <1:10) were recorded at a value of 1:5, and titers above 1:10240 were recorded at a value of 1:10240. The seroconversion rate represented a post-vaccination titer ≥1:40 in subjects with a pre-vaccination titer of <1:10 or a ≥4-fold titer increase in subjects with a pre-vaccination titer of ≥1:10. All serum samples were assayed in a blinded manner, in duplicate, and were checked in parallel by the Chinese National Institute for the Control of Pharmaceutical and Biological Products.

**Statistical analysis**

For immunogenicity assessments, the seroconversion rate represented either a post-vaccination titer ≥1:40 (in accordance with the requirements for seasonal influenza vaccines by the European Committee for Proprietary Medicinal Products) in subjects with a pre-vaccination titer of <1:10 or a ≥4-fold titer increase in subjects with a pre-vaccination titer of ≥1:10. A seroprotection rate >70% was considered to provide protection. In addition, the geometric mean increase (GMI) was the ratio of the titer after vaccination to the titer before vaccination. All the serum data analysed in this research was from the subjects who received blood collections four times (European Agency for the Evaluation of Medicinal Products (EMEA) 1997).

Hypothesis testing was conducted using two-sided tests, with an alpha value of 0.05 considered to indicate

| Table 1 Participant disposition |
|--------------------------------|
| **Dosage** | **Age** | **Dose** | **Subjects** | **Sex** | **Age, Mean** |
|------------|---------|---------|-------------|--------|---------------|
|            |         |         | Male, No.   | Female, No. | Ratio (Male : Female) |
| 15 μg      | 6 ~ 12 m| 1       | 20          | 10      | 1.001.00     | 9.70         |
|            |         | 2       | 16          | 9       | 1.291.00     | 9.63         |
|            | 13 ~ 24 m| 1       | 50          | 25      | 1.001.00     | 19.24        |
|            |         | 2       | 39          | 20      | 1.051.00     | 19.44        |
|            | 25 ~ 35 m| 1       | 50          | 26      | 1.081.00     | 29.54        |
|            |         | 2       | 42          | 22      | 1.101.00     | 29.45        |
| Total      |         | 1       | 120         | 61      | 1.031.00     | 21.94        |
|            |         | 2       | 97          | 51      | 1.111.00     | 22.15        |
| 7.5 μg     | 6 ~ 12 m| 1       | 20          | 10      | 1.001.00     | 8.30         |
|            |         | 2       | 19          | 9       | 0.901.00     | 8.42         |
|            | 13 ~ 24 m| 1       | 50          | 25      | 1.001.00     | 18.68        |
|            |         | 2       | 41          | 21      | 1.051.00     | 18.71        |
|            | 25 ~ 35 m| 1       | 50          | 25      | 1.001.00     | 29.56        |
|            |         | 2       | 44          | 22      | 1.001.00     | 29.75        |
| Total      |         | 1       | 120         | 60      | 1.001.00     | 21.48        |
|            |         | 2       | 104         | 52      | 1.001.00     | 21.50        |
| SI         | 6 ~ 12 m| 1       | 12          | 6       | 1.001.00     | 9.83         |
|            |         | 2       | 10          | 5       | 1.001.00     | 9.90         |
|            | 13 ~ 24 m| 1       | 30          | 15      | 1.001.00     | 18.53        |
|            |         | 2       | 28          | 14      | 1.001.00     | 18.57        |
|            | 25 ~ 35 m| 1       | 30          | 15      | 1.001.00     | 29.23        |
|            |         | 2       | 26          | 14      | 1.171.00     | 29.50        |
| Total      |         | 1       | 72          | 36      | 1.001.00     | 21.54        |
|            |         | 2       | 64          | 33      | 1.061.00     | 21.66        |
statistical significance. All statistical analyses were performed using the SPSS software package (version 11.5).

Results

Study participants

A total of 312 subjects between 6 and 35 months of age participated in the clinical trial. Among them, 52 subjects were 6–12 months of age, 130 subjects were 13–24 months of age and 130 subjects were 25–35 months of age. Firstly, the 312 subjects were vaccinated and 312 serum samples were collected initially. Secondly, 265 subjects were vaccinated and 265 serum samples were collected. 25 subjects were gradually withdrawn from the clinical trial and 22 subjects refused to provide the serum. After 2 doses of injection, 252 serum samples were collected and 13 subjects refused to provide the serum. The specific vaccination data including gender, months of age are shown in Table 1. Of the 312 enrolled subjects, 252 subjects (80.77%) completed the entire study, providing three serum samples.

Safety of the vaccine

The overall adverse reaction rates are shown in Figure 1. After one dose of injection, the 7.5 μg group had a mild adverse reaction rate of 10.83% and the moderate adverse reaction rate of 6.67%. The 15 μg group had a mild adverse reaction rate of 10.83% and the moderate adverse reaction rate of 8.33%. The SI group had a mild adverse reaction rate of 6.25% and the moderate adverse reaction rate of 6.25%. In all groups, no serious adverse reactions were detected. Fever was the most frequently reported adverse effect. After one dose of injection, the fever reaction rate in the 7.5 μg, 15 μg and SI group were 11.67%, 13.33% and 9.72%, respectively. After two doses of injection, the fever reaction rate in the 7.5 μg, 15 μg and SI group were 14.42%, 15.46% and 12.50%, respectively. In addition to fever, eating disorders, vomiting, diarrhea, coughing, crying and other adverse reactions have occurred in the study dose group. Except for vomiting, other adverse reactions have occurred in the SI.

Immune response

Before vaccination, the proportion of subjects showing HI ≥1:40 was 29.55% in the 6–12 months of age group with the highest observed, 18.27% in the 13–24 months of age group and 19.23% in the 25–35 months of age group (Table 1). Immune responses were induced in all subjects after vaccination. After one dose of injection, the rates of seroconversion and seroprotection in the 7.5 μg group were 39.60% and 52.48%, and the HI Geometric mean titer (GMT) growth multiple was 37.86. The rates of seroconversion and seroprotection in the 15 μg group were 48.89% and 61.11%, and the HI GMT was 51.57. After two doses of injection, the rates of seroconversion and seroprotection in the SI were all increased. The rates of seroconversion and seroprotection in the 7.5 μg group were 85.15% and 90.10%, and the HI GMT was 163.34. The rates of seroconversion and seroprotection in the 15 μg group were 92.22% and 94.44%, and the HI GMT was 221.11.

After one dose of injection, in the 7.5 μg group, the rates of seroconversion and seroprotection were 36.84% and 63.16% in the 6–12 months of age group, 34.15% and 39.02% in the 13–24 months of age group, 46.34% and 60.98% in the 25–35 months of age group. Except the rate of seroprotection in the 13–24 months of age group was lower than that of the other two groups, the rates of seroconversion and seroprotection in the 6–12 months...
and 25–35 months of age groups all had no significant difference. And in the 15 μg group, the rates of seroconversion and seroprotection were 93.33% and 93.33% in the 6–12 months of age group, 94.59% and 94.59% in the 13–24 months of age group, 89.47% and 94.74% in the 25–35 months of age group. Similarly, the rates of seroconversion and seroprotection in the three months of age groups all had no significant difference.

In the SI group, the proportion of HI ≥1:40 post-vaccination had increased slightly compared to the values of pre-vaccination (14.75%). The protection rate was 16.39% after one dose of injection and 22.95% after two doses of injection. Similarly, the GMT of the HI antibody titers was 8.34 after one dose of injection and 13.44 after two doses of injection.

In summary, in the subjects administered with two doses of 7.5 μg vaccine, the rates of seroconversion and seroprotection met the requirements specified by the EMEA (The European Agency for the Evaluation of Medicinal Products). The results showed that the vaccine could provide protection against the 2009 H1N1 virus.

### Table 2 Proportion of participants with seroprotection and seroconversion in the various groups

| Dosage | Age       | Baseline   | 21 days after injection | 42 days after injection |
|--------|-----------|------------|-------------------------|-------------------------|
|        |           | SP rate (95% CI) | SC rate (95% CI) | SP rate (95% CI) | SC rate (95% CI) |
| 15 μg  | 6-12 m    | 13.33 (3.73 ~ 37.88)^b  | 26.67 (10.90 ~ 51.95) | 33.33 (15.17 ~ 58.28) | 93.33 (70.18 ~ 98.81)^a |
|        | 13-24 m   | 32.43 (19.63 ~ 48.53)^b  | 51.35 (35.89 ~ 66.55) | 67.57 (51.47 ~ 80.37)^ib | 94.59 (82.29 ~ 98.50)^a |
|        | 25-35 m   | 21.05 (11.07 ~ 36.34) | 55.26 (39.70 ~ 69.85)^a | 65.79 (49.89 ~ 78.79)^a | 89.47 (75.86 ~ 95.83)^a |
|        | Total     | 24.44 (16.73 ~ 34.24) | 48.89 (38.82 ~ 59.05)^a | 61.11 (50.78 ~ 70.53)^a | 92.22 (84.80 ~ 96.18)^a |
| 7.5 μg | 6-12 m    | 47.37 (27.33 ~ 68.29) | 36.84 (19.15 ~ 58.96) | 63.16 (41.04 ~ 80.85)^a | 89.47 (68.60 ~ 97.06)^a |
|        | 13-24 m   | 9.76 (3.86 ~ 22.55)^a  | 34.15 (21.56 ~ 49.45) | 39.02 (25.65 ~ 54.27) | 80.49 (65.99 ~ 89.77)^a |
|        | 25-35 m   | 19.51 (10.23 ~ 34.01) | 46.34 (32.05 ~ 61.29)^a | 60.98 (45.73 ~ 74.35)^a | 87.80 (68.74 ~ 91.48)^a |
|        | Total     | 20.79 (14.02 ~ 29.70) | 39.60 (30.61 ~ 49.35)^a | 52.48 (42.83 ~ 61.95)^a | 85.15 (76.93 ~ 90.79)^a |
| SI     | 6-12 m    | 20.00 (5.67 ~ 50.98) | 0.00 (0.00 ~ 27.75) | 20.00 (5.67 ~ 50.98) | 10.00 (1.79 ~ 40.41) |
|        | 13-24 m   | 11.54 (4.00 ~ 28.98) | 3.85 (0.68 ~ 18.90) | 15.38 (6.15 ~ 33.53) | 3.85 (0.68 ~ 18.90) |
|        | 25-35 m   | 16.00 (4.60 ~ 34.65) | 0.00 (0.00 ~ 13.32) | 16.00 (6.40 ~ 34.65) | 12.00 (4.17 ~ 29.96) |
|        | Total     | 14.75 (7.96 ~ 25.72) | 1.64 (0.29 ~ 8.72) | 16.39 (9.15 ~ 27.61) | 8.20 (3.55 ~ 17.80) |

^aP < 0.05 compared with the SI group.

^bP < 0.05 compared with the 7.5 dose group.
Discussion

It is well-known that influenza can cause infection in different age stratification and spread fast. However, children and the elderly are more susceptible to influenza virus and the rates of infection are highest among children resulting in serious illness and death. In infants below 2 years old, the hospitalization rates are much higher than the older infants and children, and the risk of receiving influenza-related complications are also higher than that of other age groups (Fiore et al. 2008). So, the infants are the primary targets of the influenza vaccine to control influenza pandemic.

Some papers have reported the safety and immunogenicity of the 2009 influenza A (H1N1) vaccine in people aged >3 years old. The results showed that a single 7.5 μg of this monovalent 2009 influenza A (H1N1) vaccine can induce enough antibody responses (Greenberg et al. 2009; Liang XF et al. 2010). However, Walter EB indicated that, due to the immature immune system or not infected by the influenza virus, the vaccine induced significant lower antibody responses in infants aged <1 year old (Walter EB et al. 2010). Thus, it is necessary to study the immunogenicity of the 2009 influenza A (H1N1) vaccine in infants. Previous studies have explored the immune effect of vaccine in infants aged <3 years old. In the UK, after two 7.5 μg doses of injection with the whole virus influenza vaccine in infants aged <12 years old, the proportion of subjects showing HI ≥1:32 was 78.20% (Waddington CS et al. 2010). Among them, the proportion of subjects showing HI ≥1:32 was 65.70% in 6 months to 3 years of age. In Australia, a single 15 μg of the inactivated split-virion H1N1 vaccine caused a significant increase of the specific antibody in 86.78% of the infants aged 6 months to 9 years (Nolan et al. 2010). In South Korea, after one 7.5 μg dose of injection with the inactivated split-virion H1N1 vaccine in infants aged 6 months to 3 years, the proportion of subjects showing HI ≥1:40 was 55.90% (Chi-Eun et al. 2010).

### Table 3 Geometric mean titer (GMT) and the geometric mean increase (GMI) in the various groups

| Dosage | Age       | Baseline | 21 days after injection | 42 days after injection |
|--------|-----------|----------|-------------------------|-------------------------|
|        |           | GMT (95% CI) | GMT (95% CI)           | GMT (95% CI)           |
|        |           |           | 21 days after injection | 42 days after injection |
| 15 μg  | 6-12 m    | 7.58      | (4.34 ~ 13.24)^b        | (8.11 ~ 34.07)^b        | (1.30 ~ 3.69)^b        | (80.39 ~ 264.73)^a       | (12.32 ~ 30.08)^a       |
|        | 13-24 m   | 13.75     | (9.03 ~ 20.94)^a        | (37.46 ~ 108.97)^a      | (3.22 ~ 6.70)^a        | (170.61 ~ 382.91)^a      | (11.59 ~ 29.81)^a       |
|        | 25-35 m   | 10.37     | (6.50 ~ 16.55)^a        | (40.06 ~ 106.95)^a      | (4.14 ~ 9.62)^a        | (151.81 ~ 337.21)^a      | (13.80 ~ 34.38)^a       |
|        | Total     | 11.05     | (8.42 ~ 14.51)^a        | (37.07 ~ 71.76)^a       | (3.63 ~ 6.00)^a        | (172.15 ~ 383.99)^a      | (15.19 ~ 26.34)^a       |
| 7.5 μg | 6-12 m    | 22.32     | (9.97 ~ 49.91)^a        | (28.58 ~ 155.49)^a      | (1.85 ~ 4.81)^a        | (166.88 ~ 458.35)^a      | (7.16 ~ 21.44)^a       |
|        | 13-24 m   | 7.63      | (5.67 ~ 10.27)^a        | (15.15 ~ 42.39)^a       | (2.24 ~ 4.93)^a        | (75.11 ~ 179.31)^a       | (10.57 ~ 21.89)^a       |
|        | 25-35 m   | 10.70     | (6.87 ~ 16.65)^a        | (28.89 ~ 65.58)^a       | (2.85 ~ 5.80)^a        | (124.11 ~ 261.33)^a      | (11.20 ~ 25.30)^a       |
|        | Total     | 10.71     | (8.22 ~ 13.95)^a        | (27.83 ~ 51.50)^a       | (2.82 ~ 4.44)^a        | (127.06 ~ 209.94)^a      | (12.03 ~ 19.33)^a       |
| SI     | 6-12 m    | 9.33      | (3.62 ~ 24.08)          | (3.77 ~ 20.09)          | (0.80 ~ 1.09)          | (4.70 ~ 42.60)          | (0.69 ~ 3.31)          |
|        | 13-24 m   | 7.87      | (4.68 ~ 13.22)          | (5.51 ~ 13.18)          | (0.83 ~ 1.41)          | (7.67 ~ 18.94)          | (1.10 ~ 2.13)          |
|        | 25-35 m   | 8.71      | (5.30 ~ 14.29)          | (5.19 ~ 12.37)          | (0.81 ~ 1.04)          | (8.57 ~ 25.35)          | (1.19 ~ 2.41)          |
|        | Total     | 8.43      | (6.14 ~ 11.58)          | (6.35 ~ 10.95)          | (0.87 ~ 1.12)          | (9.74 ~ 18.54)          | (1.28 ~ 1.99)          |

*P < 0.05 compared with the SI group.

*P < 0.05 compared with the 7.5 dose group.
Our study demonstrated that a second 7.5 μg dose of this monovalent 2009 influenza A (H1N1) vaccine can induce stronger antibody responses in infants (aged 6 months to 3 years). After immunization, the rates of seroprotection and seroconversion were 90.10% and 85.15% respectively and the GMI was 15.25. The above results met the standard of vaccine immunogenicity required by European Union Committee for Medicinal Products.

Similar to many results reported previously, a higher than expected proportion of infants exhibited baseline antibody titers greater than 1:40 (Greenberg et al. 2009; Nolan et al. 2010). While we excluded infants with confirmed H1N1 infection, these results illustrated the high number of reclusive infection in infants. Our study was carried out in 8 months after the outbreak of the H1N1 virus, which increased the possibility of the people subjected with reclusive infected with influenza virus. In addition, the results showed that the proportion of the people reclusive infected with influenza virus was different in different areas of China.

In the SI group, the proportion of H1 antibody against 2009 H1N1 virus ≥ 40 was 16.39% after one dose of injection and 22.95% after two doses of injection. The seasonal vaccine did not provide protection against 2009 H1N1 virus in infants. These results were consistent with those reported in other papers that little cross-reactive antibody against the 2009 H1N1 virus after seasonal vaccination (Centers for Disease Control and Prevention (CDC) 2009).

In our study, the proportion of infants aged 6 months to 3 years showing baseline antibody titers greater than 1:40 was 20.63%. After one dose of 7.5 μg vaccine, the rates of antibody titers greater than 1:40 in three age groups were 63.16%, 39.02% and 60.98%, respectively. After one dose of 15 μg vaccine, the rates of antibody titers greater than 1:40 in the three age groups were 33.33%, 67.57% and 65.79%, respectively. These results were higher than those reported by the South Korea and lower than those reported by the Australia, which may be influenced by the baseline antibody titers (Chi-Eun et al. 2010; Nolan et al. 2010). The baseline antibody titer of different months of age groups had significant differences. After one dose of injection, the rates of seroprotection in the three months of age groups had significant differences. After two doses of injection, the rates of seroconversion and seroprotection in the three months of age groups had no significant difference. The above results showed that only two doses of injection of the monovalent 2009 influenza A (H1N1) vaccine could induce enough antibody responses in infants and also avoided the difference of the rates of seroprotection caused by the baseline antibody titer. In addition, the results also verified the recommendation of the Centers for Disease Control and Prevention, which the Advisory Committee on Immunization Practices suggested that infants and children aged 6 months to 9 years should receive 2 doses of H1N1 influenza vaccine.

Our study showed that 7.5 μg dose of the monovalent 2009 influenza A (H1N1) vaccine was well tolerated and immunogenic, which could provide protection for infants and reduce the spread of the virus in the influenza pandemic.

Abbreviations
Cl: Confidence interval; EMEA: European agency for the evaluation of medicinal products; GMI: Geometric mean increase; GMT: Geometric mean titer; HI: Hemagglutinin inhibition; SC: Seroconversion; SI: Seasonal influenza vaccine; SP: Seroprotection; WHO: World health organization.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
SLW and SQW contributed to the writing of the report. FJL participated in the recruitment of participants. WQC and JRD contributed to data interpretation. BS participated in the design of the study. ZC managed the study, served as principle investigator and gave final approval of the version to be published. All authors read and approved the final manuscript.

Author details
1 Shanghai Institute of Biological Products, Shanghai 200052, China. 2 Hunan Provincial Center for Disease Prevention and Control, Changsha, Hunan, China. 3 Institute Pasteur of Shanghai, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.

Received: 24 December 2013 Accepted: 14 July 2014 Published: 31 July 2014

References
Centers for Disease Control and Prevention (CDC) (2009) Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Mortal Wkly Rep 58(19):521–524
Dominguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espinosa-Perez L, de la Torre A, Poblano-Morales M, Balthazar-Torres JA, Bautista E, Martinez A, Martinez MA, Rivero E, Valdez R, Rius-Palacios G, Hernandez M, Stewart TE, Fowler RA (2009) Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 302(17):1880–1887
Donaldson LJ, Rutter PD, Ellis BM, Greaves FE, Myronot OT, Pebody RG, Yardley LE (2009) Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. BMJ 339:b2513
Echevarría-Zuno S, Mejía-Arangüé JM, Mar-Obeso AJ, Grajales-Muñiz C, Robles-Pérez E, González-León M, Ortégua-Alvarez MC, González-Bonilla C, Rascon-Pacheco RA, Borja-Aburto VH (2009) Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 374(9707):2072–2079
European Agency for the Evaluation of Medicinal Products (EMA) (1997) Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/BWP/214/96. Committee for Proprietary Medicinal Products (CPMP). In: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf Accessed 12 Mar 1997
Fiore AE, Shay DK, Broder K, Islander JK, Uyeki TM, Mootrey G, Bresee JS, Cox NS, Centers for Disease Control and Prevention (CDC). MMWR Recomm Rep 57(RR-7):1–60
Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, Hollingsworth TD, Griffin J, Baggaley RF, Jenkins HE, Lyons EJ, Jombart T, Hinsley WR, Grassly NC, Balloux F, Ghani AC, Ferguson NM, Rambaut A, Pybus OG, Lopez-Gatell H, Alpuche-Aranda CM, Chacala IB, Zavala EP, Guerra DM, Checchi F, Garcia E, Hugonnet S, Roth C, WHO Rapid Pandemic Assessment Collaboration (2009) Pandemic potential of a strain of influenza A (H1N1): early findings. Science 324(5934):1557–1561
Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, Basler R (2009) Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 361(25):2405–2413
Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix T, Stelfox T, Bagshaw S, Choong K, Lamontagne F, Turgeon AF, Lapinsky S, Ahern SP, Smith O, Siddiqui F, Jouvet P, Khwaja K, McIntyre L, Menon K, Hutchison J, Hornstein D, Joffe A, Lauzier F, Singh J, Karachi T, Wiebe K, Olafson K, Ramsey C, Sharma S, Dodek P et al (2009) Critically ill patients with 2009 influenza A (H1N1) infection in Canada. JAMA 302(17):1872–1879

Liang XF, WH, Wang JZ, Fang HH, Wu J, Zhu FC (2010) Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 375(9705):66–70

NIAID Division of Microbiology and Infectious Diseases (2007a) Adult toxicity table. In: http://www.niaid.nih.gov/LabsAndResources/resources/DMIDClinResch/Documents/dmidadulttox.pdf Accessed 1 Nov 2007

NIAID Division of Microbiology and Infectious Diseases (2007b) Pediatric toxicity table. In: http://www.niaid.nih.gov/LabsAndResources/resources/DMIDClinResch/Documents/dmidpedtox.pdf Accessed 1 Nov 2007

Oh CE, Lee J, Kang JH, Hong YJ, Kim YK, Cheong HJ, Ahn YJ, Kim SH, Lee HJ (2010) Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial. Vaccine 28(36):5857–5863

Ruben FL (2004) Inactivated influenza virus vaccines in children. Clin Infect Dis 38(5):678–688

Waddington CS, Walker WT, Oesper C, Reiner A, John T, Wilkins S, Casey M, Eccleston PE, Allen RJ, Okike I, Ladham S, Sheasby E, Hoschler K, Andrews N, Wood P, Collinson AC, Death P, Finn A, Faust SN, Snape MD, Miller E, Pollard AJ (2010) Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 340:c2649

Walter EB, RS, Zhu Y, Neuzil KM, Fairchok MP, Englund JA (2010) Trivalent inactivated influenza vaccine (TIV) immunogenicity in children 6 through 23 months of age: do children of all ages respond equally? Vaccine 28(27):4376–4383

World Health Organization (2009a) Statement to the press by WHO Director-General Dr Margaret Chan. World now at the start of 2009 influenza pandemic. http://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/. Accessed 11 Jun 2009

World Health Organization (2009b) Availability of a candidate reassortant vaccine virus for the novel influenza A (H1N1) vaccine development X-179A. http://www.who.int/csr/resources/publications/swineflu/candidates_X-179a/en/ Accessed 25 May 2009

World Health Organization (2010a) Pandemic (H1N1) 2009 - update 112. http://www.who.int/csr/don/2010_08_06/en/ Accessed 6 Aug 2010

Yang Z, Yang J, Wang S, Li W, Li C, Dong J (2012) The long-term immunogenicity of an inactivated split-virus 2009 pandemic influenza A/H1N1 vaccine: randomized, observer-masked, single-center clinical study. Results Immunol 2184–189

Ze C, Yang Z (2010) Pandemic Influenza Vaccine Clinical Trial Abstract Minimum InformationSummary on H1N1 vaccine in China: state manufacturers. http://www.who.int/vaccine_research/diseases/influenza/meeting_18_19Feb2010/en/informe1.html Accessed 11 Feb 2010

Cite this article as: Wang et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in infants: randomized, observer-masked, single-center clinical study. SpringerPlus 2014 3:397.

Submit your next manuscript at ➤ springeropen.com

Submit your manuscript to a journal and benefit from:
➤ Convenient online submission
➤ Rigorous peer review
➤ Immediate publication on acceptance
➤ Open access: articles freely available online
➤ High visibility within the field
➤ Retaining the copyright to your article

doi:10.1186/2193-1801-3-397